SCHEMBL5453327

SCHEMBL5453327

NC(=O)c1c(NC(=O)C2CC2)sc2c1CCOC2OCCCl

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.47
ALDH1A1 P00352 8/20 0.41
HPGD P15428 5/20 0.41
HSD17B10 Q99714 2/20 0.41
TSHR P16473 1/20 0.41
MAPK10 P53779 1/20 0.41
MDM2 Q00987 1/20 0.41
MAPT P10636 5/20 0.41
KDM4E B2RXH2 4/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CNR2 P34972 3/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
REV1 Q9UBZ9 2/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CNR1 P21554 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453699 0.89 FLT3 (0.47) FLT3ALDH1A1HPGDHSD17B10TSHR
SCHEMBL5459693 0.88 FLT3 (0.49) FLT3ALDH1A1HPGDHSD17B10TSHR
SCHEMBL5455855 0.87 FLT3 (0.45) FLT3ALDH1A1HPGDHSD17B10TSHR
SCHEMBL5449695 0.85 FLT3 (0.43) FLT3ALDH1A1HPGDHSD17B10TSHR
SCHEMBL5451643 0.78 FLT3 (0.55) FLT3ALDH1A1HPGDHSD17B10TSHR
SCHEMBL5458311 0.75 FLT3 (0.52) FLT3ALDH1A1HPGDHSD17B10TSHR
SCHEMBL5455200 0.72 FLT3 (0.46) FLT3ALDH1A1HPGDHSD17B10TSHR
SCHEMBL5449035 0.71 FLT3 (0.47) FLT3ALDH1A1HPGDHSD17B10TSHR
SCHEMBL5457860 0.71 FLT3 (0.44) FLT3ALDH1A1HPGDHSD17B10TSHR
SCHEMBL5450745 0.70 FLT3 (0.46) FLT3ALDH1A1HPGDHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885ALDH1A1 1153/4885HPGD 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.